Medtronic plc News
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
see moreMedtronic plc Market News
6h
Medtronic Secures Category I CPT Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
- Medtronic (NYSE: MDT) gained key CPT® code approvals on Oct 1, 2026, boosting coverage for its Altaviva™ and Symplicity Spyral™ platforms targeting incontinence and hypertension.
14d
Medtronic Finalizes $650 Million SPR Therapeutics Buy as Neuromodulation Revenue Begins to Flow
Medtronic wrapped up its $650M acquisition of SPR Therapeutics on July 16, 2026, and began recognizing revenue—about $5 million—in Q1 FY27.
28d
Medtronic Q1 FY2027 Beat and Raised Guidance Propels Strategic Investments in Robotics and Heart Tech
Medtronic reported stronger-than-expected Q1 FY2027 results, lifted full-year outlook, and committed ~$780M to robotics and structural heart innovation.
28 Aug at 23:55
Medtronic Approves Q2 FY2027 Dividend, Announces Q1 Earnings Release Date
Medtronic’s board approved a $0.72 per‑share dividend for Q2 FY2027 and confirmed its Q1 FY2027 earnings release will occur on September 1.
14 Aug at 23:55
Medtronic's Strategic Moves and Financial Performance in 2026
Medtronic's 2026 financial results and strategic initiatives.